

Efficacy of Nipocalimab in Adult Patients with Moderate-to-severe Ocular Manifestations of Generalized Myasthenia Gravis in Phase 3 Vivacity-MG3 Study

Kristl G. Claeys,¹ Kavita Gandhi,^{2*} Maria Ait-Tihyaty,^{2*} Ibrahim Turkoz,³ Sheryl Pease,² Charlotte Gary,⁴ Zia Choudhry,⁵ Sindhu Ramchandren,³

¹Department of Neurology, University Hospitals Leuven, and Laboratory for Muscle Diseases and Neuropathies, KU Leuven, Leuven, Belgium; ²Johnson & Johnson, Raritan, NJ, USA; ³Johnson & Johnson, Titusville, NJ, USA; ⁴Johnson & Johnson, Issy-les-Moulineaux, France; ⁵Johnson & Johnson, Horsham, PA, USA

*Presenting author
*Affiliation at the time of study

Background

- In patients with generalised myasthenia gravis (gMG), 15–50% present with ocular manifestations (ptosis, diplopia).¹⁻³
- Ocular symptoms in gMG limit daily activities (e.g., driving, reading) and significantly reduce quality-of-life.^{4,5}
- Nipocalimab, as add-on to standard-of-care (SOC), demonstrated sustained efficacy versus placebo+SOC in a double-blind, 24-week, phase 3 study (Vivacity-MG3) in adult patients with gMG.⁶
- Nipocalimab, a neonatal fragment crystallizable (Fc) receptor-binding monoclonal antibody has been approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of gMG in adult and pediatric patients (≥12 years) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.^{7,8}

Objectives

This post-hoc analysis evaluated efficacy of nipocalimab vs placebo in the subgroup of patients with moderate-to-severe ocular manifestations (MSOM)

Methods

Eligibility criteria and efficacy analysis

- **Vivacity-MG3 inclusion criteria**
 - Age: ≥18 years.
 - The Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II a/b, III a/b, or IV a/b for gMG that was not well-controlled with stable MG therapy (or, who discontinued MG therapy due to intolerance or lack of efficacy).
 - Myasthenia Gravis-Activities of Daily Living (MG-ADL) scores ≥6 at screening and baseline.
- **Analysis population**
 - MSOM population was defined as baseline score of ≥2 points on either diplopia or ptosis items of MG-ADL scale.

Endpoints and assessments

- **Endpoints assessed**
 - Mean change from baseline (CFB) to week 24 in:
 - MG-ADL-ocular scores.
 - MG-ADL-total scores.
 - Proportion achieving meaningful within-person improvement (MWPI) of ≥2 points at 24-weeks from baseline.
- **Statistical methods**
 - Mean changes were compared using Wilcoxon signed-rank test, additionally, repeated measures models were utilized to analyze least squares (LS) mean CFB to week 24.
 - Chi-square test statistics evaluated proportion achieving MWPI.
 - Logistic regression models were used to examine likelihood (odds ratio [OR]) of achieving MWPI.

Results

Baseline and demographic characteristics

- At baseline, within MSOM subgroup, nipocalimab (n=54) and placebo (n=51) arms were comparable in mean age, BMI and mean (standard deviation [SD]) MG-ADL-ocular and MG-ADL-total scores (**Table 1**).

Table 1: Patient baseline and demographic characteristics


	Nipocalimab n=54	Placebo n=51
Age, mean (SD)	52.5 (15.59)	53.5 (16.77)
Female (%)	63	55
BMI, mean (SD)	27.6 (5.56)	29.2 (5.77)
Duration of MG (years), mean (SD)	7.3 (8.01)	9.2 (8.86)
MG-ADL-total, mean (SD)	10.1 (2.8)	9.5 (1.9)
MG-ADL-ocular, mean (SD)	4.1 (1.2)	3.5 (1.0)

BMI=Body mass index, MG=Myasthenia gravis, MG-ADL=Myasthenia Gravis-Activities of Daily Living, SD=Standard deviation.

MG-ADL-total scores with nipocalimab vs placebo

- At week 24, the change from baseline LS mean difference in MG-ADL total scores was significantly greater with nipocalimab vs placebo (**Figure 1**):
 - Mean difference (SE) MG-ADL-total for nipocalimab vs placebo: -1.35 (0.680); p=0.025.

Figure 1: Change from baseline at week 24 in MG-ADL-total score



p values were calculated using Wilcoxon signed-rank test; CFB=Change from baseline, LS=Least squares, MG-ADL=Myasthenia Gravis-Activities of Daily Living, SE=Standard error.



Scan the QR code. The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

Key Takeaways

This *post hoc* analysis in patients with gMG and MSOM suggests that


✓ Nipocalimab-treated patients showed significant improvements on the MG-ADL-ocular and MG-ADL-total scores vs placebo-treated-participants.

✓ Nipocalimab-treated patients were significantly more likely to achieve meaningful within person improvement in MG-ADL at week 24 than placebo-treated-participants.

MG-ADL-ocular scores with nipocalimab vs placebo

- At week 24, the change from baseline LS mean difference in MG-ADL-ocular scores was greater with nipocalimab vs placebo (**Figure 2**).

Figure 2: Mean change from baseline at week 24 in MG-ADL-ocular domain score




p values were calculated using Wilcoxon signed-rank test; CFB=Change from baseline, LS=Least squares, MG-ADL=Myasthenia Gravis-Activities of Daily Living, SE=Standard error.

MG-ADL-ocular likelihood of achieving MWPI (≥2 point improvement) at week 24

- Significantly greater proportion of participants achieved meaningful within person improvement at week 24 on MG-ADL-ocular domain with nipocalimab than placebo (51% vs 24%); Odds ratio (95% CI): 3.23 (1.30, 8.07) (**Figure 3**).

Figure 3: Odds of achieving MWPI in MG-ADL-ocular domain score



CI=Confidence interval, MG-ADL=Myasthenia Gravis-Activities of Daily Living, MWPI=Minimum within person improvement.